Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Xponance Inc.

Xponance Inc. cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,602 shares of the specialty pharmaceutical company’s stock after selling 346 shares during the quarter. Xponance Inc.’s holdings in Jazz Pharmaceuticals were worth $1,304,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Jazz Pharmaceuticals in the third quarter valued at about $611,000. Exchange Traded Concepts LLC raised its holdings in Jazz Pharmaceuticals by 6.6% during the third quarter. Exchange Traded Concepts LLC now owns 4,604 shares of the specialty pharmaceutical company’s stock worth $596,000 after purchasing an additional 284 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Jazz Pharmaceuticals by 12.0% during the third quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company’s stock worth $3,640,000 after purchasing an additional 3,004 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Jazz Pharmaceuticals by 10.6% in the third quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock valued at $1,304,000 after purchasing an additional 962 shares during the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Jazz Pharmaceuticals by 6.3% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 35,647 shares of the specialty pharmaceutical company’s stock valued at $4,614,000 after buying an additional 2,100 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JAZZ shares. Robert W. Baird began coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $160.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $220.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Finally, Stifel Nicolaus increased their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $108.32 on Thursday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The company has a market cap of $6.82 billion, a price-to-earnings ratio of 17.70, a PEG ratio of 1.50 and a beta of 0.59. Jazz Pharmaceuticals plc has a 1 year low of $106.61 and a 1 year high of $146.70. The firm has a 50 day moving average price of $118.98 and a 200 day moving average price of $122.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.